Transcription of proteinase 3 and related myelopoiesis genes in peripheral blood mononuclear cells of patients with active Wegener's granulomatosis.

OBJECTIVE Wegener's granulomatosis (WG) is a systemic inflammatory disease that is associated with substantial morbidity. The aim of this study was to understand the biology underlying WG and to discover markers of disease activity that would be useful for prognosis and treatment guidance. METHODS Gene expression profiling was performed using total RNA from peripheral blood mononuclear cells (PBMCs) and granulocyte fractions from 41 patients with WG and 23 healthy control subjects. Gene set enrichment analysis (GSEA) was performed to search for candidate WG-associated molecular pathways and disease activity biomarkers. Principal components analysis was used to visualize relationships between subgroups of WG patients and controls. Longitudinal changes in proteinase 3 (PR3) gene expression were evaluated using reverse transcription-polymerase chain reaction, and clinical outcomes, including remission status and disease activity, were determined using the Birmingham Vasculitis Activity Score for WG (BVAS-WG). RESULTS Eighty-six genes in WG PBMCs and 40 in WG polymorphonuclear neutrophils (PMNs) were significantly up-regulated relative to controls. Genes up-regulated in WG PBMCs were involved in myeloid differentiation, and these included the WG autoantigen PR3. The coordinated regulation of myeloid differentiation genes was confirmed by GSEA. The median expression values of the 86 up-regulated genes in WG PBMCs were associated with disease activity (P = 1.3 x 10(-4)), and WG patients with low-level expression of the WG signature genes showed expression profiles that were only modestly different from that in healthy controls (P = 0.07). PR3 transcription was significantly up-regulated in WG PBMCs (P = 1.3 x 10(-5), false discovery rate [FDR] 0.002), but not in WG PMNs (P = 0.03, FDR 0.28), and a preliminary longitudinal analysis showed that the fold change in PR3 RNA levels in WG PBMCs corresponded to changes in the BVAS-WG score over time. CONCLUSION Transcription of PR3 and related myeloid differentiation genes in PBMCs may represent novel markers of disease activity in WG.

[1]  E. Baechler,et al.  Gene-expression profiling in rheumatic disease: tools and therapeutic potential , 2009, Nature Reviews Rheumatology.

[2]  D. Alcorta,et al.  Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. , 2004, Journal of the American Society of Nephrology : JASN.

[3]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[4]  G. Karypis,et al.  Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation , 2004, Genes and Immunity.

[5]  J. Banchereau,et al.  Gene expression patterns in blood leukocytes discriminate patients with acute infections. , 2007, Blood.

[6]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.

[7]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[8]  Feng Chen,et al.  Statistical analysis of real-time PCR data , 2006, BMC Bioinformatics.

[9]  C. Wijbrandts,et al.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients , 2007, Annals of the rheumatic diseases.

[10]  F. Moosig,et al.  Pathways to ANCA Production: From Differentiation of Dendritic Cells by Proteinase 3 to B Lymphocyte Maturation in Wegener’s Granuloma , 2008, Clinical reviews in allergy & immunology.

[11]  P. Gregersen,et al.  An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.

[12]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[13]  Virginia Pascual,et al.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. , 2008, Immunity.

[14]  C. Stegeman,et al.  Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. , 2004, Arthritis and rheumatism.

[15]  K. Becker,et al.  Analysis of microarray data using Z score transformation. , 2003, The Journal of molecular diagnostics : JMD.

[16]  D. Schroeder,et al.  Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis , 2007, Annals of Internal Medicine.

[17]  R J Falk,et al.  Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. , 2007, Kidney international.

[18]  J. Krischer,et al.  Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis , 2008, Annals of the rheumatic diseases.

[19]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[20]  A. Friedman,et al.  NF-κB p50 Regulates C/EBPα Expression and Inflammatory Cytokine-Induced Neutrophil Production1 , 2009, The Journal of Immunology.

[21]  P. Merkel,et al.  Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). , 2005, Arthritis and rheumatism.

[22]  A. Petersen,et al.  Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. , 2006, Blood.

[23]  J. Wieslander,et al.  Increased circulating levels of proteinase 3 in patients with anti‐neutrophilic cytoplasmic autoantibodies‐associated systemic vasculitis in remission , 2003, Clinical and experimental immunology.

[24]  D. Printz,et al.  Use of flow cytometric CD34 analysis to quantify hematopoietic progenitor cells. , 1993, Leukemia & lymphoma.

[25]  B. Thiers.  ANCA Are Detectable in Nearly All Patients with Active Severe Wegener's Granulomatosis , 2008 .

[26]  P. Seo.  Wegener's granulomatosis: managing more than inflammation , 2008, Current opinion in rheumatology.

[27]  W. Gross,et al.  Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener's granulomatosis. , 2000, American journal of respiratory and critical care medicine.

[28]  P. Merkel,et al.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). , 2001, Arthritis and rheumatism.

[29]  V. Pascual,et al.  Systemic lupus erythematosus: all roads lead to type I interferons. , 2006, Current opinion in immunology.

[30]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Relman,et al.  Gene transcript abundance profiles distinguish Kawasaki disease from adenovirus infection. , 2009, The Journal of infectious diseases.

[32]  H. McLeod,et al.  Applications of genomic tools to colorectal cancer therapeutics. , 2008, Current opinion in molecular therapeutics (Print).

[33]  V. Witko-Sarsat,et al.  Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis , 1999, FEBS letters.

[34]  M. Arnaout,et al.  Identity of Wegener's autoantigen (p29) with proteinase 3 and myeloblastin. , 1990, Blood.

[35]  J. Cowland,et al.  The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules , 1999, Journal of leukocyte biology.

[36]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[37]  Markus Ringnér,et al.  What is principal component analysis? , 2008, Nature Biotechnology.

[38]  N. Knowlton,et al.  Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. , 2008, Arthritis and rheumatism.

[39]  P. Limburg,et al.  Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. , 2000, Arthritis and rheumatism.

[40]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. G. Taylor,et al.  Target antigens for anti‐neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils , 2000, Clinical and experimental immunology.

[42]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[43]  J. Krischer,et al.  Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. , 2005, The Journal of rheumatology.

[44]  M. Petri,et al.  Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus , 2009, Lupus.

[45]  Wei Pan,et al.  A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments , 2002, Bioinform..

[46]  D. Pritchard,et al.  Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. , 2008, Arthritis and rheumatism.